Article 2: Buyer beware
Why in news: The Health Ministry has expanded Schedule H2 to cover entire therapeutic classes, strengthening QR-code based medicine tracking to curb counterfeit drugs, improve quality control, and enhance pharmaceutical supply chain transparency.
Key Details
- Risk-Based Regulation: Schedule H2 now covers entire therapeutic classes instead of selected drug brands.
- Enhanced Traceability: QR codes include product ID, licence number, batch number, and manufacturing details for tracking medicines.
- Public Health Benefits: Helps combat counterfeit medicines, antimicrobial resistance (AMR), and diversion of controlled drugs.
- Regulatory Reforms: Complements the Jan Vishwas Act, 2026 by distinguishing procedural lapses from serious non-compliance.
- Implementation Needs: Requires a real-time national database, interoperable digital infrastructure, consumer awareness, and MSME support.
Expansion of Schedule H2
- The Health Ministry has expanded Schedule H2 from a selected list of drug brands to entire therapeutic classes.
- The move shifts regulation from a revenue-based approach to a risk-based approach.
- Introduced in 2022-23, Schedule H2 required QR codes/barcodes on medicine packs to verify authenticity.
- The new system also includes:
- Product identifier
- Manufacturing licence number
- Batch number
- Other traceability details
Objectives and Significance
- Enables authorities to trace defective or counterfeit drug batches more effectively.
- Strengthens pharmaceutical quality control and supply chain transparency.
- Helps curb the circulation of:
- Fake medicines
- Counterfeit vaccines
- Cancer drugs
- Antimicrobials
- Supports safer pharmaceutical exports and regulatory compliance.
Key Concerns Addressed
- Tackles the growing problem of counterfeit medicines in India.
- Helps combat antimicrobial resistance (AMR) caused by substandard medicines and under-dosing.
- Reduces the diversion of medicinal opioids and psychotropic drugs into illegal markets.
- Addresses repeated quality concerns raised by:
- U.S. FDA
- European Medicines Agency (EMA)
- U.S. Trade Representative (USTR)
Implementation Challenges
- QR code tracking requires a real-time, government-managed digital database.
- States need interoperable software and scanning infrastructure.
- Pharmacists and consumers must regularly verify medicines before sale or purchase.
- MSME pharmaceutical manufacturers may face higher packaging and IT compliance costs.
- Prescription data on controlled medicines requires strong digital privacy and governance safeguards.
Way Forward
- Ensure effective nationwide implementation of the Schedule H2 tracking system.
- Reduce unnecessary compliance while enforcing strict action against serious violations.
- Provide financial and technical support to MSME drug manufacturers.
- Build secure digital infrastructure with robust data protection measures.
- Strengthen public awareness and pharmacist participation to improve medicine verification and restore India's reputation as the "Pharmacy of the World."
Conclusion
The expansion of Schedule H2 marks an important step towards a safer, more transparent pharmaceutical ecosystem. However, technology alone cannot eliminate counterfeit medicines. Effective implementation through digital infrastructure, strong regulatory oversight, industry support, and public participation is essential. A robust traceability system will strengthen patient safety, enhance global confidence, and reinforce India's position as the "Pharmacy of the World."